JP3050413B2 - Patch for treating skin diseases - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relieves patient pain,
The present invention relates to a patch for treating skin diseases which improves the efficiency of treatment.

[0002]

2. Description of the Related Art Ointments have been variously used as external medicines, but no ointment-containing patches for treating skin diseases have been developed yet.

[0003]

When the ointment is applied to the affected area, the patient complains of pain when the finger touches the affected area, so there is a drawback that it is difficult to use. In addition, when the affected area is wide, the ointment is applied evenly over the entire surface. There is also inconvenience that it takes time to do. Furthermore, after the ointment is applied, it is necessary to cover the applied surface with gauze, absorbent cotton, oil paper, or the like to prevent the ointment from adhering to clothes, and there is also a complaint that the practitioner takes time and effort. Therefore, development of a patch to which an ointment has been applied in advance has been desired.

[0004] Therefore, first, an ointment was applied to a support such as a non-woven fabric, and a patch was prepared by protecting the ointment surface with a plastic film (protective liner) such as polyethylene or polypropylene, like a conventional cataplasm. At the time of peeling, it was found that there was a problem that peeling was observed between the support and the ointment while the ointment remained attached to the protective liner. Various investigations have been made to solve this problem. As a result, it was found that a sheet-like layer (hereinafter, referred to as a separation layer in the present invention) having a property of being softer or more easily stretchable than the support may be interposed between the ointment and the protective liner. Heading, the present invention has been completed.

[0005]

That is, the present invention relates to FIG.
As shown in Fig. 1, a patch for treating a skin disease has a structure in which a support 1, an ointment layer 2, a separation layer 3, and a protective liner 4 are sequentially laminated. The support used in the present invention is made of a woven or non-woven fabric such as cotton, cellulose, staple fiber, chemical fiber, or a non-woven fabric, soft vinyl chloride, polyethylene, polyurethane, or the like in consideration of uniform adhesion to the affected surface. Etc. are appropriate. In particular, a woven or non-woven fabric made of cotton, staple, cellulose or the like having air permeability is preferable. These materials can also have elasticity and drape to improve the adhesion to the human body.

The separation layer used in the present invention needs to have physical properties that are softer or easier to expand than the above-mentioned support. However, its chemical nature may be the same as or different from that of the support. As these separation layers, for example, woven or non-woven fabric such as cotton, cellulose, staple fiber, chemical fiber, soft vinyl chloride, polyethylene,
A foam sheet such as polyurethane is used. Whether the separation layer is softer than the support or has a property of being easily stretched is determined by the following method.
It can be known by measuring the elongation (30% modulus) or the porosity and comparing them.

[0007] The methods for measuring the softness, elongation (30% modulus) and porosity are as follows. Measurement of bending resistance: width 2
cm and a 15 cm length of the test piece are placed on a horizontal stand of a 45 ° cantilever type test device, and the short side of the test piece is adjusted to the base line of the scale. Then, the test piece is gently moved in the direction of the slope. Slide and determine the extruded length of the test piece when one end (center) of the test piece contacts the slope. Measurement of elongation (30% modulus): width 5 cm, length 20 cm
Specimens of the above, according to JIS L1068 woven fabric tensile test method, gripping interval 10cm, pulling speed 30 ± 2cm
/ Min, and the load when the test piece is elongated by 30% is determined. Measurement of porosity: Place the sample on a mount of an appropriate color so that the pattern of the sample can be clearly seen, and make an enlarged copy. Then
Graph paper for tracing is superimposed on this, and the area of the void is measured. As is clear from the above measurement method,
It can be said that the smaller the value of the bending resistance and the elongation percentage (30% modulus) and the higher the porosity, the softer and more easily the elongation.

By using a material that is softer and more stretchable than the support as the separation layer, when the protective liner is peeled off from the patch, the separation does not occur at the interface between the support and the ointment, and the separation layer adheres to the protective liner. As it is, peeling occurs at the interface between the ointment and the separation layer. As a protective liner for protecting the separation layer, a plastic film of polyethylene, polypropylene, polyvinyl chloride, polyester, or the like, or an embossed plastic film thereof can be used.

As the ointment, an oil-based ointment, an emulsion-based ointment or a water-soluble ointment prepared according to a conventional method, for example, according to the general ointment of the Japanese Pharmacopoeia, can be used. For example, the base, some emulsifiers and stabilizers were heated and melted, mixed and kept at about 75 ° C, and the water-soluble stabilizers and emulsifiers were dissolved in water and heated to about 75 ° C. Add the ingredients, stir, cool to an appropriate temperature, add the active ingredient (active ingredient),
It is an ointment (pharmaceutical bulk) that has been stirred and homogenized.

Although what is used as the main drug (active ingredient) is not particularly limited, lysozyme is preferred in the tests. Proteinaceous drugs such as plasmin, bromelain, epidermal growth factor (EGF), and kallikrein are also used. Further, as other examples, sulfisomidines, sulfa drugs such as sulfadiazine, kanamycin,
Antibiotics such as erythromycin, chloramphenicol, and gentamicin; corticosteroids such as hydrocortisone, dexamethasone, and fluocinonide; anti-inflammatory analgesics such as diphenhydramine and indomethacin; and vitamins such as tocopherol are also included.

The spreading and coating of the ointment on the support may be carried out at room temperature or at a temperature lower than room temperature by a usual doctor knife method, T-die method, roll coating method or the like. The coating thickness of the ointment is suitably 0.5 to 5 mm, but is preferably 1 mm or more in order to sufficiently exert the therapeutic effect. In addition, in consideration of workability at the time of application to the human body, the margin of the patch from 2 to 4 mm may be kept in a state where the ointment is not applied.
When a sheet having a large porosity is used as the support, the ointment may seep out from the opening of the sheet. To prevent this, the outside of the support may be further covered with cloth, nonwoven fabric, paper or the like. The size of the patch is not particularly limited, but is preferably A6 to A3 size so that it can be used for various sizes. These patches are sealed in a sealed container made of an aluminum adhesive film or the like and stored until use.

[0012]

EXAMPLES The present invention will be described more specifically with reference to examples. Example 1 A nonwoven fabric having a rigidity of 200 mm and an elongation percentage of 0.1 kg as a support at a weight of 100 g per 1 m2 and a rigidity of 50 mm at a weight of 30 g per 1 m2 as a separation layer. ,
A nonwoven fabric having an elongation of 0.1 kg was used. 25 on support
Lysozyme ointment (reflap ointment,
Hitachi Chemical) was spread using a knife doctor to a width of 14 cm and a thickness of 1.5 mm, and a separation layer was laminated thereon,
Further, a polyester film (25 μm) was laminated on the separation layer. An ear portion of 1.5 cm was provided on one side of the ointment application portion, and cut into a length of 10 cm.
A patch for treating a skin disease having a size of × 14 cm and a size of the support, the separation layer and the protective liner of 10 × 15.5 cm was prepared. The ointment adhesion rate to the facing (separation layer + protective liner) at the time of peeling was as good as 5%.

Example 2 The support had a bending resistance of 20 mm and an elongation of 0.5 k.
g of polyethylene net, and a nonwoven fabric having a stiffness of 10 mm and an elongation of 0.01 kg was used as a separation layer.
On a support, reflap ointment stored at 25 ° C. for one day and night was spread to a thickness of 3 mm using two rolls, a separation layer was laminated thereon, and a 25 μm polyethylene film was further placed on the separation layer. Laminated. At this time, in order to prevent the ointment from oozing from the opening of the support, a nonwoven fabric weighing 100 g per square meter was further laminated on the support. At the time of use, the nonwoven fabric on the support side can be used as a cover material without being removed. This was cut in the same manner as in Example 1,
A patch for treating skin diseases was prepared. The ointment adherence rate to the facing at the time of peeling was as good as 1%.

Example 3 A gauze having a stiffness of 20 mm and an elongation of 2.0 kg was used as a support, and a stiffness of 20 mm and an elongation of 0.1 k were used as a separation layer.
g in the same manner as in Example 2 except that
A patch for treating skin diseases was prepared. The ointment adhesion rate to the facing at the time of peeling was as good as 3%.

Example 4 A polyethylene net having a porosity of 20% was used as a support, and a polyethylene net having a porosity of 50% (a rigidity of 20 mm and an elongation of 0.5 kg were the same in both cases). In the same manner as in Example 2, a patch for treating skin diseases was prepared. The ointment adhesion rate to the facing at the time of peeling was as good as 3%.

COMPARATIVE EXAMPLE As a support, a weight of 100 g per square meter and a softness of 2
The same operation as in Example 1 was performed except that a nonwoven fabric having a thickness of 0 mm, an elongation of 0.1 kg, and a porosity of 30% was used, and the same nonwoven fabric as that used for the support was used as a separation layer. The ointment adhesion rate to the facing at the time of peeling was as high as 40%.

[0017]

The dose of the ointment is easily and reliably determined by the size of the patch, so that a patch having a predetermined size may be selected and applied according to the size of the affected part. Therefore, the present invention has the effect of relieving the patient's pain and increasing the efficiency of treatment.

[Brief description of the drawings]

FIG. 1 is a cross-sectional view showing an example of a patch for treating a skin disease in the present invention.

[Explanation of symbols]

 1: Support 2: Ointment layer 3: Separation layer 4: Protective liner

──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor: Shoji Oji-machi, Okawa-gun, Ogawa-gun, Kagawa Prefecture Incorporated (58) Field surveyed (Int.Cl. ⁷ , DB name) A61K 9/70 305

Claims (4)

(57) [Claims] 1. A patch for treating a skin disease, comprising a support, a layer of an ointment, a separating layer having physical properties softer or more stretchable than the support, and a protective liner sequentially laminated thereon. 2. The surface of the support opposite to the surface in contact with the ointment,
The patch for treating a skin disease according to claim 1, which is covered with a cloth, a nonwoven fabric, or paper. 3. The separation layer according to claim 1, wherein the separation layer is in the form of a sheet.
The patch for treatment of a skin disease according to item 1. 4. The patch for treating skin diseases according to claim 1, wherein the active ingredient of the ointment is lysozyme.